Search Results - "Maier, Curtis"
-
1
Nonclinical safety assessment of engineered T cell therapies
Published in Regulatory toxicology and pharmacology (01-12-2021)“…Over the last decade, immunotherapy has established itself as an important novel approach in the treatment of cancer, resulting in a growing importance in…”
Get full text
Journal Article -
2
Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification
Published in Environmental health perspectives (01-10-2022)“…Key characteristics (KCs), properties of agents or exposures that confer potential hazard, have been developed for carcinogens and other toxicant classes. KCs…”
Get full text
Journal Article -
3
Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
Published in The FASEB journal (01-06-2023)“…Immuno‐oncology (IO)‐based therapies such as checkpoint inhibitors, bi‐specific antibodies, and CAR‐T‐cell therapies have shown significant success in the…”
Get full text
Journal Article -
4
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
Published in Advanced drug delivery reviews (01-05-2014)“…Alveolar macrophage (AM) responses are commonly induced in inhalation toxicology studies, typically being observed as an increase in number or a vacuolated…”
Get full text
Journal Article -
5
In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
Published in European journal of nuclear medicine and molecular imaging (01-02-2023)“…Purpose Sotrovimab (VIR-7831), a human IgG1κ monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain…”
Get full text
Journal Article -
6
Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey
Published in Regulatory toxicology and pharmacology (01-06-2024)“…Immunotoxicology/immunosafety science is rapidly evolving, with novel modalities and immuno-oncology among the primary drivers of new tools and technologies…”
Get full text
Journal Article -
7
Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates
Published in PloS one (23-04-2020)“…Despite the potential for the chemokine class as therapeutic targets in immune mediated disease, success has been limited. Many chemokines can bind to multiple…”
Get full text
Journal Article -
8
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Published in Regulatory toxicology and pharmacology (01-07-2009)“…An evaluation of potential antibody formation to biologic therapeutics during the course of nonclinical safety studies and its impact on the toxicity profile…”
Get full text
Journal Article -
9
Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation
Published in The Journal of experimental medicine (07-10-2002)“…Ionic signaling pathways, including voltage-dependent potassium (Kv) channels, are instrumental in antigen-mediated responses of peripheral T cells. However,…”
Get full text
Journal Article -
10
Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice
Published in Infection and Immunity (01-02-2001)“…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
11
Proteomic stabilization of Cynomolgus Macaque blood with PROT-1 for flow cytometric analysis of activated innate and adaptive immune cells after extended storage
Published in The Journal of immunology (1950) (01-05-2021)“…Abstract Flow cytometry is a widely used, and rapidly evolving, immunophenotyping application; however, limited advancements around sample stability and…”
Get full text
Journal Article -
12
Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody
Published in Cancer research (Chicago, Ill.) (15-03-1998)“…Our goal was to use carcinoembryonic antigen (CEA) as a target for immunotherapy in CEA-positive cancer patients who are all immune tolerant to the native…”
Get full text
Journal Article -
13
The Use Of A Novel Stereological Sampling Approach To Estimate Islet, Duct And Acinar Total Cell Number And Compartment Volume In Nonhuman Primate Pancreas
Published in The FASEB journal (01-04-2016)“…Abstract only Design‐based stereology is used to obtain quantitative estimates of biological structures from sections with known precision and unlike…”
Get full text
Journal Article -
14
Unique Molecular Surface Features of in vivo Tolerized T Cells
Published in Proceedings of the National Academy of Sciences - PNAS (14-04-1998)“…Differential expression of surface markers can frequently be used to distinguish functional subsets of T cells, yet a surface phenotype unique to T cells…”
Get full text
Journal Article -
15
Drug-induced activation of immune function: Mechanisms and potential adverse effects
Published in Journal of pharmacological and toxicological methods (01-09-2009)Get full text
Journal Article -
16
IMMUNOPHARMACOLOGY OF RECOMBINANT HUMAN INTERLEUKIN-18 IN NON-HUMAN PRIMATES
Published in Cytokine (Philadelphia, Pa.) (07-10-2002)“…Recombinant human interleukin (IL)-18 (rHuIL-18) has a potential as a therapeutic agent in cancer and is currently in drug development. Since human IL-18…”
Get full text
Journal Article -
17
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
Published in Osteoarthritis and cartilage (01-08-2015)“…Summary Objective/Method Aggrecanase activity, most notably ADAMTS-5, is implicated in pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs)…”
Get full text
Journal Article -
18
Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation
Published in Nature biotechnology (01-04-1996)“…We have developed peptide analogs to analyze precise human CD4 substructures involved in MHC class II binding. Forms of the complementarity determining-like…”
Get full text
Journal Article -
19
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
Published in mAbs (04-07-2017)“…The market for biotherapeutic monoclonal antibodies (mAbs) is large and is growing rapidly. However, attrition poses a significant challenge for the…”
Get full text
Journal Article -
20
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies
Published in Regulatory toxicology and pharmacology (01-02-2021)“…With the growth of monoclonal antibodies and other proteins as major modalities in the pharmaceutical industry, there has been an increase in pharmacology and…”
Get full text
Journal Article